Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss-based biopharmaceutical company, Debiopharm, has acquired rights to co-develop and commercialize Sigma-Tau's first-in-class luso-inotropic agent which is currently in phase II development for the treatment of acute heart failure. Financial terms of the deal were not disclosed.
Subscribe to our email newsletter
Istaroxime was identified, patented and developed up to phase I by Italian pharmaceutical company Sigma-Tau. Under the terms of the agreement, Debiopharm has the right to develop and commercialize istaroxime worldwide except in Italy and has an option to acquire similar rights on istaroxime follow-on compounds.
Debiopharm will pay an upfront license fee and milestones to Sigma-Tau and will fund the future clinical development costs for the compound.
Upon Debiopharm’s completion of the phase II clinical development program, Sigma-Tau may exercise its semi-exclusive rights to market istaroxime in Spain and France and exclusive rights in Portugal.
Royalties will accrue to both Debiopharm and Sigma-Tau according to a specific contractual mechanism.
“Istaroxime is just the type of molecule that Debiopharm favours; a promising innovative product in a disease area with an unmet need. Together with Sigma-Tau, I am hopeful that we will very quickly be able to offer patients a unique, more targeted new treatment for systolic and diastolic dysfunction,” said Rolland-Yves Mauvernay, president and CEO of The Debiopharm Group.